Baxter Hlthcare Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAXTER HLTHCARE, and when can generic versions of BAXTER HLTHCARE drugs launch?
BAXTER HLTHCARE has two hundred and eighteen approved drugs.
There are sixteen US patents protecting BAXTER HLTHCARE drugs. There are two tentative approvals on BAXTER HLTHCARE drugs.
There are thirty-seven patent family members on BAXTER HLTHCARE drugs in thirteen countries and three hundred supplementary protection certificates in fifteen countries.
Summary for Baxter Hlthcare
| International Patents: | 37 |
| US Patents: | 16 |
| Tradenames: | 330 |
| Ingredients: | 129 |
| NDAs: | 218 |
Drugs and US Patents for Baxter Hlthcare
Expired US Patents for Baxter Hlthcare
Paragraph IV (Patent) Challenges for BAXTER HLTHCARE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Inhalation | 99.90% | ➤ Subscribe | 2008-09-11 |
| ➤ Subscribe | Injection | 10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags | ➤ Subscribe | 2014-01-31 |
International Patents for Baxter Hlthcare Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 208956 | ⤷ Try a Trial |
| China | 105288650 | ⤷ Try a Trial |
| Japan | 2018052991 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2021183752 | ⤷ Try a Trial |
| South Korea | 101314803 | ⤷ Try a Trial |
| Canada | 3170514 | ⤷ Try a Trial |
| Japan | 4923144 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Baxter Hlthcare Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2380576 | 2020/043 | Ireland | ⤷ Try a Trial | PRODUCT NAME: DEOXYCHOLIC ACID SODIUM SALT; NAT REGISTRATION NO/DATE: PA2103/003/001 20170602; FIRST REGISTRATION NO/DATE: SE/H/1547/001/DC 20160729 |
| 0253310 | SPC/GB95/010 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215 |
| 0694547 | 2002/028 | Ireland | ⤷ Try a Trial | PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013 |
| 0496835 | SPC/GB96/053 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: DOXORUBICIN SULPHATE; REGISTERED: UK EU/1/96/011/001 19960621; UK EU/1/96/011/002 19960621 |
| 0480717 | 98C0025 | Belgium | ⤷ Try a Trial | PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215 |
| 2404919 | PA2016015,C2404919 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOKSOL-5-IL)CIKLOPROPANKARBONIL)AMINO)-3-METILPIRIDIN-2-IL)BENZOINE RUGSTIS ARBA JOS FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA ESTERIS; REGISTRATION NO/DATE: EU/1/15/1059 20151119 |
| 0984957 | C300483 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMTRIHYFRAAT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20110524 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
